Can riociguat REPLACE PDE-5is for PAH?
17 Sep 2020
byAudrey Abella
Patients with pulmonary arterial hypertension (PAH) experienced clinical improvement when they switched from a phosphodiesterase type 5 inhibitor (PDE-5i) to riociguat, highlighting the latter’s potential as a treatment alternative in this setting, results of the REPLACE* study have shown.
